Patents by Inventor Glenn Dranoff

Glenn Dranoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230013364
    Abstract: Combination therapies comprising antibody molecules that specifically bind to PD-1 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: December 13, 2021
    Publication date: January 19, 2023
    Inventors: Glenn Dranoff, Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Publication number: 20220364055
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: August 30, 2019
    Publication date: November 17, 2022
    Inventors: Louise Treanor, Michael R. Greene, Jennifer Brogdon, Boris Engels, Glenn Dranoff, Olja Kodrasi, Hyungwook Lim, Akash Sohoni, Elizabeth Dorothy Pratico, Anniesha Hack, Aida Abujoub, Tony Fleming, Lu Huang, Connie Hong, John Blankenship, Brian Holmberg, Chonghui Zhang, Dexiu Bu, Andrew Price, Xu Zhu, Andrew Stein, Attilio Bondanza
  • Publication number: 20220296581
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Application
    Filed: June 6, 2022
    Publication date: September 22, 2022
    Applicants: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
  • Patent number: 11382905
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: July 12, 2022
    Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
  • Publication number: 20220153835
    Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: September 30, 2021
    Publication date: May 19, 2022
    Inventors: Glenn DRANOFF, Frederic TRIEBEL, Chrystelle BRIGNONE, Walter A. BLATTLER, Jennifer Marie MATARAZA, Catherine Ann SABATOS-PEYTON, Hwai Wen CHANG, Gerhard Johann FREY
  • Publication number: 20220133889
    Abstract: Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: September 17, 2021
    Publication date: May 5, 2022
    Inventors: Glenn Dranoff, Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Publication number: 20220002382
    Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: April 2, 2021
    Publication date: January 6, 2022
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Matthew Vanneman, Gordon Freeman
  • Publication number: 20210284737
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: October 23, 2020
    Publication date: September 16, 2021
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • Publication number: 20210220404
    Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.
    Type: Application
    Filed: November 25, 2020
    Publication date: July 22, 2021
    Inventors: Aida Abujoub, John Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu, Serena De Vita, Glenn Dranoff, Boris Engels, Tony Fleming, Brian Walter Granda, Michael R. Greene, Carla Patricia Guimaraes, Anniesha Hack, Brian Holmberg, Connie Hong, Lu Huang, Olja Kodrasi, Joni Waiee Lam, Hyungwook Lim, Elizabeth Dorothy Pratico, Andrew Price, Akash Sohoni, Andrew Marc Stein, Louise Treanor, Chonghui Zhang, Xu Zhu
  • Publication number: 20210214459
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 15, 2021
    Inventors: Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Kulandayan Kasi Subramanian, Marie-Louise Fjaellskog, John Delmas Venable, III, Bianka Prinz, Jerry M. Thomas, Andrew Lake, Scott Chappel, Pamela Holland, Michael Warren, Alison Paterson, Rachel W. O'Connor, Michael Gladstone, Jonathan Hill, Christine Miller
  • Publication number: 20210139914
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 13, 2021
    Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Publication number: 20210130434
    Abstract: Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 6, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Ryan Sullivan, Matthew Vanneman
  • Publication number: 20210123075
    Abstract: The present disclosure is directed to genome editing systems, reagents and methods for immunooncology.
    Type: Application
    Filed: June 7, 2019
    Publication date: April 29, 2021
    Inventors: Ming-Wei CHEN, Glenn DRANOFF
  • Publication number: 20210015860
    Abstract: The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof.
    Type: Application
    Filed: April 9, 2020
    Publication date: January 21, 2021
    Inventors: Jennifer BROGDON, Daniela CIPOLLETTA, Glenn DRANOFF, Deborah A. KNEE, Fei WANG
  • Patent number: 10876120
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: December 29, 2020
    Assignees: DANA-FARBER CANCER INSTITUTE, INC, THE GENERAL HOSPITAL CORPORATION
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Patent number: 10865233
    Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: December 15, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Matthew Vanneman, Gordon Freeman
  • Patent number: 10865232
    Abstract: Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 15, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Ryan Sullivan, Matthew Vanneman
  • Patent number: 10851165
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: December 1, 2020
    Assignees: Novartis AG, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • Publication number: 20200345714
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Application
    Filed: July 13, 2020
    Publication date: November 5, 2020
    Applicants: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
  • Patent number: 10793633
    Abstract: The present disclosure provides, in part, compositions comprising peptides that immunospecifically bind to a defined binding partner, such as MHC class I polypeptide-related sequence A (MICA), or an epitope thereon. In some embodiments, the peptides comprise one or more complementarity determining regions relating to the complementarity regions shown in Table 1. The disclosure also provides methods of treating cancer in a subject using the compositions disclosed herein, and methods of isolating human antibodies from cancer patients following immunotherapy.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 6, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kai W. Wucherpfennig, Bettina Franz, Kenneth F. May, Jr., Glenn Dranoff, F. Stephen Hodi, Christopher Harvey